The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 24th 2025
A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
AstraZeneca’s Camille Hertzka Addresses rPFS in mCRPC
April 12th 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.
Watch
Based on the analysis of electronic health records from 480 clinics, we found that better care quality and continuity are associated with better-than-expected wound healing performance.
Read More
Identifying Complex Patients Using Adjusted Clinical Groups Risk Stratification Tool
In this study, the authors developed a method for use in primary care to identify a group of patients with complex care needs using Aggregated Diagnosis Groups.
Read More
Pharmacist Hypertension Management Using an Electronic Health Record–Based Approach
The authors studied the impact of a pharmacist intervention on blood pressure control compared with usual care.
Read More
Dr Shoaib Ugradar Addresses Presenting Patients With Treatment Options and Informing Them About AEs
April 11th 2022While teprotumumab, a new FDA-approved therapy for thyroid eye disease (TED), has its adverse events, the other options to treat TED can have severe consequences, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Watch
Biomarker Identifies CRSwNP Endotypes, Risk of Postoperative Nasal Polyp Recurrence
April 9th 2022Circulating B cell–activating factor was shown to be a potential biomarker in identifying blood eosinophil counts and risk of postoperative nasal polyp recurrence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC
April 8th 2022Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.
Read More
Dr Bernice Kwong Discusses Impact of Delayed Diagnosis, Treatment for GVHD
April 8th 2022Bernice Kwong, MD, clinical professor of dermatology, Stanford University, talks about how later diagnosis and treatment for graft-versus-host disease (GVHD) affects disease progression and overall patient outcomes.
Watch
Formulary Placement Led to Delays, Disruptions in Receiving Sacubitril/Valsartan for CHF
April 8th 2022More than a quarter of patients experience disruptions and delays in treatment for chronic heart failure (CHF) after the initial prescription for sacubitril/valsartan was abandoned/rejected.
Read More
Older EoE Patients More Likely to Respond to Topical Corticosteroids, Study Finds
April 8th 2022Recent clinical trials have excluded older patients with eosinophilic esophagitis (EoE) from participating; however, patients aged 65 years and older are more likely to respond to topical corticosteroids than their younger counterparts.
Read More
Genomic Profiling Utility for Targeted Therapy Selection Shown in Advanced GI Cancers
April 8th 2022The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.
Read More
Equivalent Safety, Efficacy Between Herceptin and Trastuzumab Biosimilar for Gastric Cancer
April 7th 2022A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.
Read More
Dr Jorge Plutzky: New Advances in Science, Medicine Need to Move Into Practice Quicker
April 6th 2022The acceleration of science and medicine is exciting, but these new advances are not always moving into practice, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital, and associate professor of medicine at Harvard Medical School.
Watch